These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 15827606)

  • 21. Impact of host and virus genome variability on HCV replication and response to interferon.
    Schweitzer CJ; Liang TJ
    Curr Opin Virol; 2013 Oct; 3(5):501-7. PubMed ID: 23835049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
    Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
    Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients.
    Sherman KE; Shire NJ; Rouster SD; Peters MG; James Koziel M; Chung RT; Horn PS
    Gastroenterology; 2005 Feb; 128(2):313-27. PubMed ID: 15685543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection.
    Torriani FJ; Ribeiro RM; Gilbert TL; Schrenk UM; Clauson M; Pacheco DM; Perelson AS
    J Infect Dis; 2003 Nov; 188(10):1498-507. PubMed ID: 14624375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiviral treatment of hepatitis C virus infection and factors affecting efficacy.
    Zhu Y; Chen S
    World J Gastroenterol; 2013 Dec; 19(47):8963-73. PubMed ID: 24379621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current and future concepts in hepatitis C therapy.
    Pawlotsky JM
    Semin Liver Dis; 2005 Feb; 25(1):72-83. PubMed ID: 15731999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis C virus genetic variability in patients undergoing antiviral therapy.
    Cristina J; del Pilar Moreno M; Moratorio G
    Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C virus replication in mouse cells is restricted by IFN-dependent and -independent mechanisms.
    Nandakumar R; Finsterbusch K; Lipps C; Neumann B; Grashoff M; Nair S; Hochnadel I; Lienenklaus S; Wappler I; Steinmann E; Hauser H; Pietschmann T; Kröger A
    Gastroenterology; 2013 Dec; 145(6):1414-23.e1. PubMed ID: 23973921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of host metabolism as a target of new antivirals.
    Ikeda M; Kato N
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1277-89. PubMed ID: 17897752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of interleukin-8 in hepatitis C virus infection: relation to combined peg-interferon ribavirin response and genotype 4.
    El Sayed ZM; Mansour FA; Ghal MF; Abou-Zahra SB
    Immunol Invest; 2011; 40(1):29-38. PubMed ID: 20809700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.
    Zeuzem S; Schmidt JM; Lee JH; von Wagner M; Teuber G; Roth WK
    Hepatology; 1998 Jul; 28(1):245-52. PubMed ID: 9657119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Achievement of sustained viral response after switching treatment from pegylated interferon α-2b to α-2a and ribavirin in patients with recurrence of hepatitis C virus genotype 1 infection after liver transplantation: a case report.
    Kawaoka T; Hiraga N; Takahashi S; Takaki S; Tsuge M; Nagaoki Y; Hashimoto Y; Katamura Y; Miki D; Hiramatsu A; Waki K; Imamura M; Kawakami Y; Aikata H; Ochi H; Tashiro H; Ohdan H; Chayama K
    Intervirology; 2012; 55(4):306-10. PubMed ID: 21865660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New Therapies for Hepatitis C Virus.
    Polenakovik H
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(2):119-32. PubMed ID: 27442378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutations in the NS5A gene of hepatitis C virus subtype 1b and response to peg-IFNα-2a/RBV combination therapy in Azerbaijani patients.
    Bokharaei-Salim F; Keyvani H; Salehi-Vaziri M; Sadeghi F; Monavari SH; Mehrnoush L; Alavian SM
    Arch Virol; 2014 Nov; 159(11):2893-9. PubMed ID: 25139545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
    Sagnelli E; Pisaturo M; Martini S; Sagnelli C; Filippini P; Coppola N
    Expert Opin Pharmacother; 2014 Jul; 15(10):1337-49. PubMed ID: 24773464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients.
    Neumann A; Polis M; Rozenberg L; Jackson J; Reitano K; McLaughlin M; Koratich C; Dewar R; Masur H; Haagmans B; Kottilil S
    AIDS; 2007 Sep; 21(14):1855-65. PubMed ID: 17721093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigational drugs for hepatitis C.
    Flisiak R; Parfieniuk A
    Expert Opin Investig Drugs; 2010 Jan; 19(1):63-75. PubMed ID: 20001555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C.
    Paraná R; Schinoni MI; de Freitas LA; Codes L; Cruz M; Andrade Z; Trepo C
    Liver Int; 2006 Nov; 26(9):1148-54. PubMed ID: 17032416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A genetic screen identifies interferon-α effector genes required to suppress hepatitis C virus replication.
    Fusco DN; Brisac C; John SP; Huang YW; Chin CR; Xie T; Zhao H; Jilg N; Zhang L; Chevaliez S; Wambua D; Lin W; Peng L; Chung RT; Brass AL
    Gastroenterology; 2013 Jun; 144(7):1438-49, 1449.e1-9. PubMed ID: 23462180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Hepatitis C: the recovery].
    Marcellin P
    Gastroenterol Clin Biol; 2009; 33(8-9):819-29. PubMed ID: 19541439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.